Results 11 to 20 of about 1,109,815 (338)
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen+3 more
wiley +1 more source
Factors modulating 99mTc‐MAA planar lung dosimetry for 90Y radioembolization
Abstract Purpose To investigate the accuracy and biases of predicted lung shunt fraction (LSF) and lung dose (LD) calculations via 99mTc‐macro‐aggregated albumin (99mTc‐MAA) planar imaging for treatment planning of 90Y‐microsphere radioembolization.
Benjamin P. Lopez+4 more
wiley +1 more source
Abstract Background Ultrasonography (US) and 99mTechnetium‐sestamibi scintigraphy (99mTc‐MIBI) are currently first‐line imaging modalities to localize parathyroid adenomas with sensitivities of 80% and 84%, respectively. Therefore, finding other modalities to further improve the diagnostic accuracy for preoperative localization is critically needed ...
Fangyi Liu+7 more
wiley +1 more source
Exercise as cardiovascular medicine
Physical inactivity is a major modifiable contributor to the global burden of cardiovascular disease (CVD) morbidity and mortality.In this article, a clinical case study is used to provide practical approaches for general practitioners and their teams to individualise exercise prescriptions for patients with hypertension who are at risk of CVD.
Garrahy, E+6 more
openaire +5 more sources
The rise of cardiovascular medicine [PDF]
Modern cardiology was born at the turn of the nineteenth to twentieth centuries with three great discoveries: the X ray, the sphygmomanometer, and the electrocardiograph. This was followed by cardiac catheterization, which led to coronary angiography and to percutaneous coronary intervention.
Eugene Braunwald, Eugene Braunwald
openaire +2 more sources
Nano-Medicine in the Cardiovascular System [PDF]
Nano-medicines that include nanoparticles, nanocomposites, small molecules, and exosomes represent new viable sources for future therapies for the dysfunction of cardiovascular system, as well as the other important organ systems. Nanomaterials possess special properties ranging from their intrinsic physicochemical properties, surface energy and ...
Danielle Pretorius+4 more
openaire +4 more sources
Efficacy and Safety of “Kyushin” in Mongolian Patients with Ischemic Heart Disease and Heart Failure
Objectives: This study aimed to investigate the efficacy and safety of Kyushin in addition to conventional drug therapy. Methods: This study included 109 (Male/Female = 44/65) subjects were assigned to two groups (Kyushin and conventional treatment vs ...
Altaisaikhan Khasag+5 more
doaj +1 more source
The year in cardiovascular medicine 2020: arrhythmias [PDF]
AbstractSummary of the progress in arrhythmias in 2020. RACE4 and ALL-IN indicated that integrated nurse-led care improves outcomes in AF patients.3 , 4 The same was reported for early rhythm control therapy15 and cryoablation as initial AF treatment.25 , 26 Subcutaneous ICD was non-inferior to classical transvenous ICD therapy in PRAETORIAN.54 One
Harry J G M Crijns+4 more
openaire +8 more sources
Exosomes in Cardiovascular Medicine [PDF]
Exosomes are small, extracellular membrane-bound particles that mediate intercellular transport of a cytosolic cargo. Exosomal transfer of micro-RNA can modify gene expression in targeted cells. Exosome-based endocrine/paracrine signaling has been shown to be involved in a wide range of physiological processes including those associated with ...
openaire +4 more sources
Pharmacogenetics in Cardiovascular Medicine [PDF]
Pharmacogenetics is an important component of precision medicine. Even within the genomic era, several challenges lie ahead in the road towards clinical implementation of pharmacogenetics in the clinic. This review will summarize the current state of knowledge regarding pharmacogenetics of cardiovascular drugs, focusing on those with the most evidence ...
Nita A. Limdi, Sony Tuteja
openaire +3 more sources